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ABSTRACT
Development of Novel Biomarkers in Cancer: Detection of Circulating miR141 as a Potential Prognostic Marker for Prostate Cancer
by
Jason Cadaoas Gonzales
Dr. Ronald K. Gary, Examination Committee Chair
Associate Professor
University of Nevada, Las Vegas
Prostate cancer (CAP) is the most common epithelial malignancy and the
second leading cause of cancer deaths in American men. The identification of
predictive and prognostic biomarkers in CAP patients is critical for improving
clinical outcomes. Although the measurement of prostate-specific antigen (PSA)
and radiographic studies are clinically approved to predict response to therapy,
these tests can oftentimes prove to be inadequate in certain patients. Thus, it is
important to discover new biomarkers to improve chances of survivability. We
and others have shown that longitudinal measurements of circulating tumor cells
(CTC) and lactate dehydrogenase (LDH) may aid in predicting response to
therapy. More recently, levels of microRNA (miRNA) have been implicated in
disease processes such as cancer.

Specifically, the expression of human

miRNA miR-141 has been found to be elevated in the plasma of CAP patients.
In our study, we have measured the levels of miR-141 in 21 CAP patients and
compared it with other clinical markers (CTC, LDH, and PSA). We longitudinally
examined these markers alone and in combination in relationship to the patient’s
clinical course and response to therapy. Our aim was to determine if miR-141
iii

has the potential to be a putative marker for the prognosis of a patient’s response
to therapy.
For this retrospective study, plasma from 21 CAP patients were collected at
different time points corresponding to treatment regimen or follow-up
appointments. Levels of miR-141 in plasma were measured using quantitative
RT-PCR and compared to temporal changes in miR-141, CTC, LDH, and PSA
levels.

Using PSA as the standard marker in monitoring CAP, correlation

coefficients were determined for each biomarker’s capability in predicting clinical
outcomes.

Our results indicate that there is a strong correlation between a

patient’s clinical characteristics and the plasma levels of miR-141. With further
testing, we suggest that miR-141 has the potential to be a marker for the
prognosis of CAP. We find that miR-141 is largely concordant with the other
conventional markers and establish that miR-141 is a relevant biomarker worthy
of further investigation.
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CHAPTER 1
INTRODUCTION
1.1 Overview of prostate cancer
In 2006, there was a reported 2.4 million deaths in America with cancer and
cardiovascular diseases as the two leading causes of these deaths.

More

specifically, cancer was responsible for 559,000 deaths alone (1). In 2009, there
will be 1.4 million newly diagnosed cancers and approximately 562,000 deaths
attributed to cancer. It is estimated that in 2010, cancer deaths will surpass heart
disease in deaths (2).
For men, the three most commonly diagnosed cancers are prostate, lung and
gastrointestinal (GI) (3).

In terms of cancer deaths in men, prostate cancer

(CAP) is one of the leading causes and second only to lung cancer.
Approximately one in six American men will be diagnosed with CAP in their
lifetime. In 2009, there will be an estimated 192,000 new cases whereas another
one in six, approximately 27,000, will die from the disease.
Little is known as to what causes CAP. However, its increased prevalence
has garnered more interest in discovering the biochemical and physiological
functions associated with the disease. Although the pathophysiology is still not
clearly elucidated, CAP is known to originate in glandular tissue of the prostate.
A widely considered model has been proposed involving a population of
precursor cells known as high-grade prostatic intraepithelial neoplasia (PIN).
These precursor cells are normally isolated within the prostate gland, but can
eventually become malignant and form tumors (4).
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Many genes or gene

products have been associated with the development and progression of CAP. A
mutation in oncogenes such as c-myc and Ras results in a constitutive activation
or gain-of-function which results in accelerated growth or facilitates abnormal cell
division (5-14).

On the other hand, mutations in tumor and metastasis

suppressor genes such as PTEN, p53 and CD44 results in loss-of-functions (1522).

A proposed multistep process of prostate carcinogenesis involves a

progressive accumulation of these genetic alterations that facilitate the
transformation from normal prostate tissue to PIN and eventually to full blown
CAP.
For CAP patients that have tumors isolated within the capsule of the prostate
gland, the disease can be cured with therapy such as a prostatectomy or
radiation therapy. However, as the disease progresses and becomes metastatic,
curing it requires more surveillance and therapy.

Metastatic CAP is

heterogeneously comprised of two types of malignant cells: androgen-dependent
and androgen-independent (23, 24). Androgens are steroid hormones that aid in
the development and maintenance of male characteristics such as testes
formation and spermatogenesis (25). In androgen-dependent cells, higher levels
of androgens can repress the transcription of death-signaling genes necessary
for apoptosis (26, 27). Therapies that are targeted to suppress or block the
production of androgen (androgen ablation therapy) are aimed to allow the
expression of these death-signaling genes (28, 29).

In contrast, androgen-

independent cells are resistant to any levels of androgens. These subsets of
cells are considered castrate-resistant and are therefore insensitive to any type
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of androgen ablation therapies (30, 31). The lethality of advanced CAP can
mainly be attributed to this castrate-resistant form of the disease (32).
Although significant advances have been made in understanding the
molecular biology of CAP, this disease continues to be a major health problem.
Knowing the risk factors and understanding the screening and therapies
available can help in reducing the burden of this disease.

1.2 Risk factors associated with prostate cancer
There are several common risk factors associated with CAP: age, ethnicity,
familial disposition, and diet. Of these factors, age appears to be very important
(33).

CAP is usually rare for men under the age of 40, but the incidence

dramatically increases with age progression, with the most dramatic prevalence
of CAP occuring between the ages of 61-80 years (34, 35).
African-American men are more at risk of developing CAP. The average
incidence for African-American men in their 70s is approximately 1,600 per every
100,000. This is approximately 1.5x the incidence for Caucasians and 2x the
rate in Asian-Americans (36-38). It has also been reported that age of onset of
CAP in African-Americans is earlier than most other ethnicities.

Other studies

have also discovered that at the time of diagnosis, diagnostics markers, such as
prostate-specific antigen (PSA) and biopsy scores (Gleason score), and
progression of disease were elevated or more advanced in African-Americans
than in any other ethnic group (39, 40). There is no solid understanding for the
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disparate figures regarding the risks in African-Americans; however poor access
to healthcare and education have been suggested (41).
Studies have shown that men who have first-degree relatives diagnosed with
CAP have an increased risk for CAP. For example, a man with at least one other
immediate family member diagnosed with CAP has twice the risk of being
diagnosed themselves. This incidence increases approximately 5- and 10-fold
when two or more family members are affected (42-47). Another study has also
linked prognosis of survival as a potential genetic predisposition whereas a son’s
survival can be directly correlated to his father’s outcome (48).
Clearly, age and race seem to strong risk factors when ascertaining one’s
likelihood of developing CAP.

Although it may seem apparent that one can

closely predict who will be diagnosed with CAP based on age or genetic
predispositions, clinical tests must be performed to properly diagnose CAP.
Unfortunately, the clinical presentation of this disease may be subtle and present
asymptomatically. It has been said that most men will die with CAP as opposed
to dying from it. An autopsy study analyzing serial sections of the prostate found
that one-third of men 80 years or younger had CAP whereas in men greater than
80, two-thirds were positive for CAP (49).

1.3 Methods of screening
As with most cancers, early detection is essential for survival. In fact, the
five-year survival rate for men diagnosed with cancer presenting localized or
regional spreading is close to 100 percent. If the disease has progressed to a
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more malignant, invasive form, there is a meager 31.9 percent survival rate (33).
Men who clinically present often have difficulty urinating or have a feeling of
discomfort in their pelvic region.

Unfortunately, CAP can be present

asymptomatically and the need of sensitive and specific screening is needed.
Many tests exist for the screening of CAP. Digital rectum exams (DRE) and
determination of prostate specific antigen (PSA) levels are some of the more
common methods of diagnosis. Least common tests include prostate biopsies
and transrectal ultrasonography; however these are not used for primary
screening due to either cost, availability or their potentially low sensitivity and
specificity in detecting CAP.
PSA is a protein produced by prostate epithelial cell and has a half-life of
approximately 2 days (50). Total serum PSA has been found to be increased in
men with CAP and thus has been detected with elevated levels in the serum of
CAP patients. The increase in detectable PSA in the serum is due to a disruption
of the tissue barriers between the prostate gland lumen and the capillary.
Unfortunately, PSA levels can also be increased in the men exhibiting enlarged
prostates, also known as benign prostatic hyperplasia (BPH). Prostatitis, digital
rectal exams, ejaculation, and prostate biopsies can also lead to an increase of
PSA in serum (51-56).
To assess an abnormal PSA level in the serum, a cutoff of 4.0ng/mL has
been established. At this level, studies have determined the PSA sensitivity and
specificity is at an estimated 70 to 80 percent and 60 to 70 percent, respectively
(57).

Furthermore, the positive predictive value (a measure of the ability to
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accurately identify CAP in men with elevated PSA levels) of PSA levels between
4.0 -10ng/mL was determined to be at 30 percent (58-60). This predictive value
increases to approximately 64 percent if PSA levels are determined to be greater
than 10ng/mL (61).
To improve on the accuracy of PSA’s diagnostic capabilities, it has been
proposed to use multiple PSA parameters instead of a single PSA measurement.
A few of these parameters include measuring free, unbound PSA, the change of
PSA levels over time (PSA velocity), and PSA levels per unit volume of prostate
(PSA density) (62). In some instances, men with PSA levels below 4.0ng/mL are
found to have CAP; therefore some physicians have suggested lowering the
cutoff to 2.5ng/mL (63-66). The effort to improve the diagnostic power of PSA
has yielded multiple potential modifications; however there has been no
consensus as to which of these modifications can be used to improve diagnosis
or clinical outcomes.

A major focus in CAP research is determining new

prognostic serum markers with increased sensitivity and specificity.
Anatomical examinations such as the digital rectal exam can detect
abnormalities of the prostate. These abnormalities include asymmetry, nodules,
or hardening (induration of the prostate). A DRE can detect CAP in the lateral
and posterior aspects of the prostate glands; however, 85 percent of cancers
occur on the periphery and can only be detected by examination with a finger
(67).

Most cases of CAP that are diagnosed solely through a DRE present a

clinically advanced stage of the disease (68).

In fact, multiple studies have

shown the specificity of the DRE to be at 59 percent, with a sensitivity of 94
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percent and an overall positive predictive value of 28 percent (69). The low
specificity and late disease onset of detection with DRE make it a test best used
in conjunction with other tests such as PSA screening. Studies have shown that
combining the PSA and DRE has greatly improved the rate of CAP detection
(70).
For patients with high PSA levels and an abnormal DRE, a prostate biopsy
can be performed to confirm a CAP diagnosis. In certain instances, CAP can be
diagnosed solely through a prostate biopsy. A biopsy is a procedure where a
small piece of suspected tissue is extracted from a patient using a needle. The
resultant tissue is called a biopsy core. The cores are assessed to determine if
cells of the tissue are normal or cancerous. Specifically, prostate biopsies are
performed rectally through the perineum, with the use of a biopsy gun to extract
cores of tissues (71). Approximately six needle cores are extracted from the
base, midzone and apical areas of the prostate gland; however studies suggest
the assessment of ten needle cores can increase the detection rate (72-75).
For CAP patients, biopsies of tumors are performed to assess the
progression of the disease. Tumor biopsies are performed in the same manner
as exploratory biopsies and are given numerical grades based on the
differentiation and structure of the cells present in the tumor. Cells with normal
structure and differentiation are given a grade of one, whereas cells with the least
amount of structure and differentiation are scored a five. The grades ascertained
from the biopsy cores are called the Gleason grade (76). In most instances,
multiple cell types are exhibited in the core (i.e. a core exhibits cells with a grade
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of 3 and 4).

In situations where multiple grades exist, the core is given a

combined score of the two highest-graded cell types exhibited in the core (i.e. a
score of 7 where cell types of grade 3 and 4 exist). These combined Gleason
scores allow physicians to determine the grade or severity of cancer present:
combined scores of two through four represent a low-grade cancer; scores five
through seven are considered moderate-grade; scores eight through ten are
considered high-grade cancers (77, 78).
Another characteristic of a tumor biopsy that can increase clinical information
is the extent of the biopsy that is occupied by the tumor. Whereas a Gleason
score is a measure of cell differentiation of a tumor, this estimated tumor volume
is determined by the amount of biopsy cores that are positive for tumor
involvement and the percentage of the tumor involvement within each positive
core. Together with the level of cell differentiation of a tumor (Gleason score),
the extent of biopsy cores that are positive for tumors, and the percentage the
tumor that is occupied within each positive core, a biopsy can provide more
clinically significant information (79, 80).

1.4 Risks associated with screening
The value in screening for CAP lies in a test’s ability to reduce the morbidity
and mortality of this disease. Currently, only two large randomized trials have
sought to determine the effectiveness of current screening methods – the
European Randomized Study of Screening for Prostate Cancer (ERSPC) and the
United States Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening
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Trial.

In both studies, men were randomly selected to have interval PSA

screenings; however in the PLCO study, a DRE supplemented the PSA
screening (81, 82).

The tests were used to determine which patients should

receive biopsies and ultimately receive proper treatment. Collectively, the two
studies determined that the absolute mortality benefit from screening was
relatively low. Meaning, these studies suggest that the current methods and
frequency of screening for CAP may not help to prevent death versus those who
do not regularly screen for CAP.
The low efficacy of the current screening methods may lead to potential harm
from screening. Prostate biopsies, for instances, can lead to high anxiety, pain,
and in rare cases, serious complications that can lead to hospitalization (83, 84).
Even after a patient undergoes a biopsy, there is potential for a negative biopsy
result which can lead to increased anxiety due to the high false-negative rates
(85). Furthermore, there is an issue of an over diagnosis, whereas the detection
of conditions through screening may not actually prove to be clinically significant.
An over diagnosis can subject patients to unnecessary subsequent testing and
rigorous treatment increasing the chances of harming the individual.
Although early screening for CAP with PSA and DRE can increase overall
survivability, patients must be informed of the inherent risks involved with
screening. Questions regarding quality of life be must be answered to weigh out
the benefits of increased screening and treatment. The absolute risk reduction
associated with screening is relatively low; therefore men who fall under certain
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risk factors (i.e. race and family history) or those who are willing to accept the
risks involved would more likely benefit from screening.

1.5 Treatment of prostate cancer
There are multiple options to treat CAP. Physicians most often strategize
their approaches for treatment based on PSA values, age, and overall health of
the patient. A more notable approach to delineating treatment options is based
on the stage and grade of the disease.

Treatment options for patients with

clinically localized CAP are approached differently than those who have a more
advanced progression of the disease (86).
Treatment option for men with localized CAP include: an active surveillance
approach, radical prostatectomy and radioactive therapy. The active surveillance
approach is an accepted option for patients exhibiting a form of the CAP that has
a relatively low risk of progression or for patients with a high risk of side effects
from certain treatments (87). This approach involves the postponement of
immediate therapy, with treatment administered only if the patient is at increased
risk or exhibits symptoms of disease progression (88). This surveillance method
can drastically reduce the potential for over-treatment or unnecessary risk of
harm to the patient.
As cancers progress to a more advanced stage, the disease is more likely to
become metastatic and affect other tissues or organs. One of the more common
organs involved in the metastatic form of CAP is the bone (89). For men with an
advanced or recurring form of CAP, a more aggressive therapy must be
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administered.

Aside from a prostatectomy and localized radiation therapy,

systemic (whole body) therapy would be a follow up option.

Normal and

cancerous prostate cells growth are stimulated by androgens; therefore, a
systemic therapy approach to metastatic CAP would be androgen deprivation
therapy (ADT).

ADT can be achieved through surgical castration, chemical

castration or a combination of both.

Unfortunately, a form of CAP exists that is

androgen-independent which would render ADT useless. This castrate-resistant
prostate cancer (CRPC) is most often treated with chemotherapy (90). However,
a new form of treatment involving the use of immunotherapy has recently been
introduced to help treat CRPC (91, 92). Provenge (Sipuleucel-T) is a form of
therapeutic cancer vaccine that utilizes a subset of a patient’s leukocytes to
present an immune-activating antigen. The immune response activates T-cells
and is clinically shown to reduce the risk of death by 22% compared to placebo
(93).

1.6 New and potential biomarkers
Biological markers, or biomarkers, refer to a measurable biological molecule
that can reference or indicate any signs of normal or abnormal biological
processes. Biomarkers can be used to diagnose and indicate the clinical stage
of disease (94). Using biomarkers for diagnosing diseases has traditionally been
focused on detecting enzymes and proteins circulating in the blood, other bodily
fluids or tissues. PSA, a serum biomarker, is actively secreted by the prostate
gland into semen and, in lower instances, other bodily fluids. Low levels are
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released into the bloodstream and are a normal occurrence; however injury,
inflammation, enlargement, or other traumatic events affecting the prostate can
increase the amount of PSA being released into the bloodstream (95, 96).
Aside from diagnosing a disease, biomarkers can be powerful tools capable
of predicting disease outcomes, predicting therapy response or identifying
patients susceptible to severe side effects.

The use of markers to evaluate

disease progression is known as a surrogate marker (97).

Surrogate markers

are biomarkers that can substitute for a clinical endpoint (94). A clinical endpoint
is a reference to the distinct overall well-being of a patient undergoing treatment.
A few of these parameters include how a patient feels, how they are functioning,
or ultimately if they have survived (94). Using such markers to predict outcome
behavior has given rise to the notion of personalized medicine – a course of
treatment tailored to each patient’s specific tolerance or the potential increase in
drug efficacy based on the genetic makeup or biochemical expressions specific
to each individual.
The current state of biomarkers has expanded to include the detection of
intact, circulating cells in the bloodstream. A growing number of studies have
focused on detecting circulating tumor cells (CTC) in blood as another potential
biomarker for disease (98, 99). The CellSearch™ Circulating Tumor Cell test,
developed by Veridex, LCC, is currently used to monitor breast and colorectal
cancers and, in February of 2008, was also approved for its ability to assess CAP
(100, 101). Using this test, prognosis for metastatic breast and CAP is defined
by the number of tumor cells detected in 7.5mL of blood.
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CTCs are prepared from whole blood in a two-step process: First, epithelial
cell adhesion molecule (EpCAM) positive cells are selected using ironconjugated EpCAM antibodies. Enrichment of EpCAM+ cells is achieved using a
pull-down method utilizing magnets.

Second, CD45 (leukocyte cell marker),

cytokeratin (marker for keratin-containing intermediate filaments) and nucleic
acids are stained via allophycocyanin (APC)-labeled antibody, phycoerythrin
(PE)-labeled antibody and 4',6-diamidino-2-phenylindole (DAPI), respectively.
The captured CTCs are imaged and scored based on the following criteria:
cytokeratin+, CD45-, and DAPI+. Figure 1 summarizes the process to enrich and
analyze for CTCs.
Detection of whole, intact cells characterized by CTCs is a clear indication of
metastatic disease and has proven to be a strong indicator of disease
progression. Studies have determined that a CTC count of five or greater as an
independently predictive parameter of a decreased progression-free survival and
overall survival (OS). More specifically, the detection of CTCs has shown to
correlate well with the progression of metastatic castration-resistant CAP (102).
Aside with being used as prognostic disease marker, CTCs may be useful in
validating other biomarker candidates (103, 104).
The detection of circulating markers found freely in human bodily fluids is not
limited to proteins or whole cells.

More recently, studies have shown the

potential of detecting circulating nucleic acids as a marker for diseases.
Detection of abnormalities in DNA has long been used to diagnose disease;
however, there are increasing studies focusing on the detection of RNA in
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determining disease states. A species of RNA, microRNA (miRNA), has shown
potential to be a marker for diseases. These miRNAs are shown, amongst other
functions, to regulate gene expression.

Figure 1: A schematic representation of CTC capture and analysis. Constituents
of whole blood for patients with CAP are summarized in panel A. The whole
blood is processed in a ferrofluid containing iron-coupled anti-EpCAM antibody to
immunomagnetically enrich for EpCAM+ cells and remaining cells are stained
with fluorescent antibodies against CD45 and cytokeratin (Panel B). Nucleic acid
is stained and the captured cells are imaged. CTCs are defined as cytokeratin +
and CD45- (panel c; red box), whereas leukocytes are CD45+ and cytokeratin-.
Cell photographs in panel c are courtesy of Dr. Louis M. Fink and Kristine
Scarbrough.

Mature miRNAs, the functional form of miRNA, are described as a 22
nucleotide (nt) species of non-coding RNA. The biogenesis of mature miRNA is
preceded by two intermediates: a pri-miRNA and pre-miRNA (Figure 2). PrimiRNA is the initial transcription product of the miRNA-bearing gene and is
characterized by a stem-loop structure. The opposing end of the stem loop is
14

cleaved by the Drosha RNase III endonuclease and yields the pre-miRNA. The
pre-miRNA is exported into the cytoplasm and the loop end of the pre-miRNA is
cleaved by the Dicer endonuclease leaving a short, 22nt, double-stranded RNA
species. This double-stranded RNA is separated into the single-stranded mature
miRNA by a helicase. The regulation of gene expression by miRNA is achieved
through either translational repression or a site-directed cleavage of the mRNA
(105, 106).

Figure 2: The biogenesis of microRNA. 1) The gene containing the miRNA is
transcribed. The transcription product is called pri-miRNA and has a stem-loop
structure. 2) The pri-miRNA is cleaved at the tail and is now called the premiRNA. 3) The pre-miRNA is exported into the cytoplasm and undergoes more
modification (cleavage and denaturation) to yield the mature miRNA. Image
adapted from Ambion website (107).

Since their initial discovery in 1993, the number of miRNA has expanded
rapidly and the Sanger miRBase sequence database now contains over 900
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characterized human miRNA (108). One of the first characterized miRNA, lin-4,
was found in the roundworm Caenorhabditis elegans (C. elegans) and was
determined to regulate the expression of lin-14 gene (109). Today, it is well
documented that miRNA play a major role in gene regulation and in certain
disease processes (110, 111). For example, miRNA expression is known to be
regulated in cancers such as chronic lymphocytic leukemia, and in lung and
thyroid cancers (112-114).
Accurate determination of treatment efficacy is important to increase the
overall survivability of CAP. It is therefore beneficial to expand on the current
repertoire of prognostic serum biomarkers. Initial efforts to identify a putative
marker can be expensive and must be validated to prove its prognostic
capabilities. Fortunately, current validated markers can be used to compare and
aid in the validation of the predictive characteristics of a putative prognostic
marker.

1.7 Purpose of the study
Discovering novel biomarkers for diagnosing or prognosing diseases such as
cancer was a major focus of my study. I have attempted to assess a variety of
potential biomarkers that would allow for accurate monitoring of disease
progression in breast and prostate cancers. My preliminary focus was aimed at
developing both a protein-based and gene expression assay (through the
detection of messenger RNA) for the simultaneous detection of SALL4 and BMI1
proteins in prostate and breast cancer. Furthermore, access to patient serum
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samples has allowed me to assess the potential for a biomarker assay, currently
marketed as a cancer biomarker panel that was developed with an emphasis
towards ovarian cancer, to detect the progression of breast cancer.
A major hurdle of clinical and translational studies can be the availability and
integrity of patient samples.

The progression of my biomarker studies was

complicated by such challenges.

For instance, a change in samples

procurement policies has impeded our access to more patient samples and an
issue of sample degradation in banked samples complicated certain aspects of
my study.

We were fortunate, however, to have enough samples to focus

attention to the detection of circulating miRNA in CAP. The focus of my thesis
will be this on this miRNA study in prostate cancer; however I present a
preliminary assessment of a cancer biomarker panel and its potential utility in
detecting breast cancer can be found in appendix figure A1. Furthermore, our
preliminary results of the gene expression assay for the detection of SALL4 and
BMI1 in breast cancer can be found in appendix figure A2.

A table that

summarizes all experiments or attempts to detect novel biomarkers in prostate
and breast cancer can be found in appendix table A1.
CAP is one of the leading causes of cancer deaths in American men.
Physical and anatomical examinations such as the digital rectal and prostate
biopsies are performed to detect and diagnose CAP. Furthermore, detection of
biomarkers has also been used to diagnose and monitor CAP. Examples of
these biomarkers include the prostate specific antigen (PSA) and lactate
dehydrogenase (LDH).

Currently, more emphasis has been placed in
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discovering new diagnostic and monitoring tools for the early detection and
accurate prognostication of this disease.

Accurately monitoring the disease

during a treatment regimen will allow physicians to determine the efficacy of the
current treatment and can allow for punctual changes in treatment regimen. Just
as PSA can aid in the diagnosis of CAP, PSA is also used as a predictive marker
for monitoring disease.
Although tests such as the prostate biopsies and detection of PSA have been
used confidently for many years, each test has known specificity and sensitivity
drawbacks. It is for those reasons that physicians often use tests in conjunction
with one-another, rather than individually, to diagnose or monitor the progression
of CAP. Furthermore, tests such as the prostate biopsy are highly invasive and
can lead to painful side effects. Digital rectal exams, although not invasive, can
cause pain and stress to patients. An ideal test would have increased specificity
and sensitivity than those of current tests and would ideally be less invasive and
painful to the patients. Biomarkers are thought to be ideal in that these are
normally detected from a patient’s blood - meaning it is non-invasive and pain
would only be measured from a patient’s tolerance to needle-stick procedures.
A recent study by Mitchell et al. discovered that human miR-141 was stable
and detectable in plasma of CAP patients (115).

miR-141 is encoded on

chromosome 12 and is a part of the miR-200 family known to regulate the
transition from epithelial to mesenchymal tissue. This morphological change in
cells reduces intercellular contacts and is a characteristic of metastasis (116118). Nevertheless, the exact role of miR-141 in CAP is currently unclear. In this
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study, we quantitate the circulating levels of miR-141 in plasma of castrationresistant and hormone-sensitive metastatic CAP patients undergoing treatment
and retrospectively compared it to levels of PSA, CTC and LDH - conventional
biomarkers used to monitor CAP. Temporal changes in copy number of
circulating miR-141 were compared to the other markers and it was determined if
miR-141 concomitantly correlated with values of the conventional markers
determined at the same time points.
The purpose of this study is to demonstrate the possible benefits of using
miR-141 as a biomarker through its correlation with treatment response. We
hypothesize that values of miR-141 detected in patient plasma are concordant
with values of PSA and clinical assessments and can prove to be a marker for
the prognosis of CAP.
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CHAPTER 2
METHODS
2.1 Chemicals, reagents and equipment
Trizol

LS

Reagent

was

obtained

from

Invitrogen

(Carlsbad,

CA).

Diethylpyrocarbonate (DEPC)-treated water was obtained from EMD Chemicals
(Gibbstown, NJ). 99.5% A.C.S. grade, 200 proof ethanol was obtained from
Acros Organics (Morris Plains, NJ). PCR reaction tubes were obtained from
VWR (West Chester, PA).

Molecular biology certified chloroform and

isopropanol was obtained from IBI Scientific (Peosta, IA). Ribooligonucleotides
for the generation of standard curves were obtained from Integrated DNA
Technologies (Coralville, Iowa).

7500 Fast Real Time PCR Thermocycler,

reverse transcription kits for the cDNA amplification of Caenorhabditis elegans (c.
elegans) miRNA cel-miR39 and Homo sapien miRNA hsa-miR-141, TaqMan
MicroRNA Assays, 96-well Thermocylcing Plate, and MicroAmp Optical Adhesive
PCR sealing film were obtained from Applied Biosytems (Foster City, CA).
miRVana miRNA extraction kit and THE RNA Storage solution were obtained
from Ambion (Austin, TX). Sterilization of equipment and work surfaces from
RNase and DNA contamination was performed with RNase Away and DNA Away
obtained from Molecular BioProducts (San Diego, CA).
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2.2 Biological sample collection
All patients and control subjects were consented by staff of the Nevada
Cancer Institute and all biological samples pertaining to this study were stored on
site in the institute’s biorepository.

Control samples were collected from

consenting volunteers that, to the best of their knowledge, were known to be
cancer-free. Biological samples of control subjects were kept anonymous and
did not have any clinical tests performed on them (i.e. PSA or CTC testing). CAP
patients used in this study were patients of Nevada Cancer Institute. In most
instances, biological samples were collected in conjunction with their treatment or
follow up visits.
For this retrospective study, CAP samples were chosen by one physician to
reflect a range of clinical biomarker changes (rising or declining PSA and CTC
values) against which miR-141 could be compared. These samples were chosen
prior to the determination of miR-141 values. All samples were collected and
processed under approved Institutional Review Board (IRB) protocols. These
samples were chosen independent of the patient’s clinical assessment, where
one’s clinical assessment is the diagnosis and prognosis of the patient based on
medical history, performance and clinical lab tests.

Each patient’s clinical

assessment was determined by one consulting oncologist and was based on
overall chart review and reflects clinical and/or radiographic disease progression.
Each assessment was made independently and in a blind fashion in respects to
all biomarker values.
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Blood was collected in K2-EDTA tubes from CAP patients with ages ranging
from 60-77 at the time of first blood draw. Each tube was centrifuged at 3,300
rpm for 10 minutes to separate the peripheral blood platelet pool. Plasma was
aspirated from the tubes, aliquotted into cryogenic tubes and stored at -80°C until
analysis. A separate sample of blood was used to run PSA, LDH and CTC
analysis on these CAP patients. The PSA was run on serum samples using the
Bayer-Centaur methodology, CTC analysis was done according to Veridex’s
standard operating protocol, and LDH was determined using the Olympus LD
procedure.

All approved clinical testing were performed by licensed clinical

laboratory staff. Each CAP patient also had subsequent blood draws at different
time points coinciding with their schedule of therapy, thus allowing a longitudinal
analysis for each biomarker. All control subjects were closely age-matched and
were subjected to one blood draw only; therefore control samples do not have
longitudinal analyses.

2.3 Determination of miR-141 expression
MicroRNA was extracted from plasma using the mirVana PARIS kit protocol
(Ambion) (15). A modification of the extraction protocol was performed by
including a second organic extraction with phenol:chloroform (Ambion) of total
RNA prior to final purification of miRNA.
To normalize the reactions, we utilized an exogenous miRNA species not
detected in human plasma, cel-miR-39 - an miRNA expressed exclusively in
Caenorhabditis elegans (c. elegans). For most expression assays, normalization
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is achieved through the detection of endogenous controls. Endogenous controls
are most often associated with the detection of constitutively expressed proteins
such as the housekeeping genes β-actin and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH); however the normalization of studies utilizing miRNA
has been complicated by the absence or inability to detect a true endogenous
species of miRNA. Furthermore, since the mechanism of circulating miRNA in
prostate cancer has not been deduced, nor has there been any true
establishment of circulating endogenous miRNA, the nature of our study has
further complicated the establishment of an endogenous control. Therefore, the
use of an exogenous control was necessary. 500pg of synthesized cel-miR-39
ribo-oligonucleotide was spiked into each plasma sample following an initial
denaturing step and served as our normalization, positive and loading miRNA
control (IDT; cel-miR-39 sequence 5’-rUCACCGGGUGUAAAUCAGCUUG-3’).
The resulting miRNA was eluted using THE RNA storage solution (Ambion) and
either immediately subjected to a reverse transcription reaction or stored at 80°C.
In order to determine absolute quantitation of miRNA, standard curves were
generated

for

both

cel-miR-39

and

miR-141

using

synthesized

ribo-

oligonucleotides in separate reaction vessels (IDT; miR-141 sequence 5’rUAACACUGUCUGGUAAAGAUGG-3’). A 6-point standard curve was created
starting with an RNA concentration of 100pg/μL with subsequent 10-fold dilutions
with DEPC-treated water to a final concentration of 1.00fg/μL.

Reverse

transcription of miR-141 and cel-miR-39 from extracted samples and standard
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curves was achieved using a TaqMan miRNA Reverse Transcription Kit (Applied
Biosystems) with specific stem-loop primers for each miRNA to be assessed
(Figure 3; Applied Biosystems). Reverse transcription reactions were incubated
in a PTC-200 thermocycler (MJ Research) under the following conditions: 16°C
for 30 minutes, 42°C for 30 min, 85°C for 5 min, and then held at 4°C (23).

Figure 3: Principle of reverse transcription to produce cDNA template from
miRNA using a looped primer. The unique stem-loop structure of the primer
allowed for high specificity of binding of miRNA species only.

Quantitative RT- PCR for each sample and standard curve was performed in
triplicate in a reaction mixture of TaqMan miRNA target-specific probe (Applied
Biosystems) and 2x Universal PCR Master Mix (Applied Biosystems) in a final
volume of 5uL. PCR reactions were performed in a 96-well thermocycling plate
sealed with optically-clear sealing film and were run under the following
conditions in 7500 Fast PCR Thermocycler (Applied Biosystems): non-fast
conditions with an initial enzyme activation of 95°C for 10 min, followed by 40
cycles of 95°C for 15 seconds, 60°C for 1 minutes where data was collected at
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the 60°C step. Although TaqMan signals were recorded at the last step of each
cycle, the data were analyzed at the final cycle of the reaction (last step of cycle
40).
Our determination of miR-141 copy number for each sample was an endpoint
analysis and the signal was interpreted into the amount of miR-141 determined
on each sample based on a linear regression equation extrapolated from our
standard curve. Figure 4 is a representative standard curve and extrapolated
equation observed throughout the study.

Normalization of the reaction was

based on the cycle threshold values from the spiked endogenous control (celmiR-39). Calculation of miR-141 copy number was as previously described (18).

Standard Curve
25
y = -3.2165x + 13.866
2

R = 0.9852

Cycle Threshold

20
15
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Figure 4: A representative standard curve to determine miR-141 concentration.
Each standard curve represents the correlation of input RNA vs. expected. A
linear regression equation was used to extrapolate the miR-141 concentration for
each sample in the study. PCR efficiency can also be determined from the slope
obtained in each reaction.
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Aside from an extrapolated input miRNA concentration, we are also able to
determine the efficiency of our qRT-PCR from our standard curves. In theory, a
reaction efficiency of 100% should yield a PCR reaction where products are
doubling after each subsequent cycle.

Using the slope obtained from the

standard curve, a measure of exponential amplification and PCR efficiency can
be determined.

A slope of -3.3 yields an exponential amplification of 2

(conferring a doubling of PCR product from previous cycles) and an efficiency of
100%. Throughout the study, we experienced an average slope of -3.42 that
yielded an average exponential amplification of 1.96 and an average PCR
efficiency of 96.1%.

2.4 Statistical methods
To assess the statistical relevance of the temporal changes of biomarker
values, each data point was transformed to a log10 value. The transformed data
for each interval were used as data points on a regression plot yielding a slope
corresponding to the temporal rate of biomarker change. Slopes were calculated
for each biomarker and for each patient separately and were used as the
outcome variables for the analyses described below.

All analyses were

conducted on two separate cohorts: cohort 1 included patients with exactly two
blood samples and cohort 2 included patients with 3 or more blood samples. For
all statistical analyses, we chose PSA as the predictor because it is considered
the gold standard biomarker used to assess response to therapy of CAP.
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1. Analysis of variance for each cohort.
a. Group 1 was defined as all patients with increasing PSA
(positive PSA slope). Group 2 was defined as all patients with
decreasing PSA (negative slope).
b. Analysis of variance was conducted for the 4 slopes (PSA, LDH,
CTC’s, and miRNA) as a function of Group as defined above.
PSA slope ANOVA is biased because the PSA slopes defined
the groups. Results for PSA are still provided for descriptive
purposes.

2. Correlation analysis. Pearson correlation coefficients were calculated
for the 4 slopes: PSA vs LDH, PSA vs CTC, PSA vs miR-141, LDH vs
CTC, LDH vs miR-141, and CTC vs miR-141.

3. Binary Classification analysis
a. Binary variables were calculated for each of the 4 biomarker
slopes. A “1” was assigned if the slope was positive. A “0” was
assigned if the slope was negative.
b. Sensitivity and specificity were calculated for 3 pairs of
biomarkers using PSA as the standard.
c. Sensitivity and specificity for other combinations were also
calculated.
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CHAPTER 3
RESULTS
The miR-141 values of the control samples are summarized in table 1 and
observed value ranges are given in table 2.

The clinical assessments and

biomarker values for each patient in this study are summarized in table 3. For
clarification of clinical assessments, patients deemed “regressing” is a patient
that is clinically performing better, whereas a “progressing” patient has clinically
gotten worse. The values of the clinical markers were not used to assess each
patient as this would confound the analysis; rather the clinical assessments were
based on the following weight-bearing percentages in determining the
assessment: radiographic progression accounted for 50% of the assessment,
performance status had a 30% weight, progression of pain at 15%, the need to
change therapies was weighed at 5%, and other systemic symptoms such as
anorexia or fatigue had <1% weight.
To assess the ability of miR-141 to prognosticate CAP, we observed two
characteristics in regards to changes in miR-141 compared to the other clinical
markers: 1) we sought to determine if temporal changes of miR-141 values
would be concordant with the changes in other markers and its potential to
correlate with clinical assessments and 2) the statistical relevance in which miR141 can accurately and precisely correlate and classify a patient against the
standard markers. When analyzing the results, biomarker data is separated into
two cohorts: 1) patients providing only two data points (one interval) and 2)
patients that had three data points to compare (two intervals). Each data point
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corresponds to separate dates of sample draws and biomarker determination.
The time lapsed between each data point differed for each patient and any
matching intervals were strictly coincidental.

3.1 Raw temporal changes of miR-141 values
Figure 5 demonstrates the raw fold-change in each biomarker between the
interval for each patient in cohort 1 (n=8 patients). Figure 6 demonstrates the
same fold changes in the two intervals for patients in cohort 2 (n=13 patients).
The significance of the raw biomarker change is defined by the ability of miR-141
value to change in concordance with the other markers in either a positive or
negative manner. In doing so, we can estimate the potential for miR-141 to
predict clinical progression.
Of the eight patients in cohort 1, 6/8 (75%) patients had all biomarkers
changes in concordance with one another. Meaning, fold changes in miR-141,
PSA and CTC either increased or decreased in the same direction during the
time intervals. For patients 7 and 14 (25% of cohort population), only two of the
three biomarkers were concordant with one another. Since PSA is used as a
standard assessment tool in progression of this disease, an important
observation can be made for patient 7: as PSA went down so did his miR-141
value with an overall clinical assessment of regression. Whereas in patient 14, a
clinically progressing patient, miR-141 and CTC values both decreased, with a
net increase in PSA. It is important to note, however, that markers changes
observed in this patient may reflect the emergence of a second metastatic
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neoplasm (pancreas cancer) during the course of treatment of the metastatic
CAP. However an autopsy was not done to confirm the presence of two
malignancies.
For patients in cohort 2, two intervals were observed.

For five patients

(patients 6, 5, 8, 17, and 21), all biomarkers were concordant with one another
during both intervals (38% of cohort). Two patients (patients 1 and 12) had the
biomarkers concordant in only the first interval (15% of cohort). Four of the
patients (patients 9, 15, 18, and 20) had observed concordant biomarkers in the
second interval only (30% of cohort). Finally, two patients (patients 16 and 19)
did not observe any three marker concordance in either one of the two intervals
(15%). Interestingly, of all interval data points that were observed (between both
cohorts), only one patient had a miR-141 change not be in concordant with
another biomarker – patient 16. During interval 1 for this patient, PSA and CTC
changes were observed to be concordant with each other; specifically, miR-141
value decreased where PSA and CTC increased. Clinically, this patient had a
slowly progressing disease during that interval and the PSA and CTC values
reflected that.

During this patient’s second interval, the disease rapidly

progressed, but PSA had a net decrease, where both miR-141 and CTC
increased.
Table 4 illustrates the degree of concordance each biomarker had with each
patient’s clinical assessment. Keeping in mind that the true clinical assessment
was ascertained independent of the biomarkers, this assessment of biomarker
concordance is based on the biomarker interval change and the actual clinical
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assessment. Conventional logic deems a clinically progressing disease should
be associated with an increase of a biomarker and vice versa for a clinically
regressing disease. For this assessment, each biomarker was given a “+” if the
change in marker was concordant with the clinical assessment and given a “-“ if it
was not; meaning if the clinical assessment was deemed progressive, each
biomarker should illustrate net increase and scored with a “+”.
The first draw for each patient was labeled as baseline (designated “b”) and
therefore a concordance score could not be assessed. A total of 34 intervals
were assessed in the study (combined all patients).

For PSA, 29/34 (85%)

intervals were concordant with the clinical assessment whereas the other
markers had 27/34 (79%), 25/34 (74%) and 24/34 (71%) for CTC, miR-141 and
LDH clinical concordance respectively.

3.2 Statistical analysis
One-way variance of analysis (ANOVA) was performed to determine if there
was a significant difference between the two groups (positive versus negative
slope), in their respective marker of study. This analysis would give us an initial
indication whether any of the markers could differentiate a regression or
progression prognosis based on marker values alone. Tables 5 (cohort 1) and 6
(cohort 2) provide the p values of both cohorts for each group compared to the
tested biomarkers. In cohort 1, we observed p<0.001 for PSA values between
the two groups. LDH, CTC had values of p=0.172 and p=0.154, respectively and
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miR-141 had p=0.007. In cohort 2, the p-values were p<0.001, p=0.277, p=0.007
and p=0.024 for PSA, LDH, CTC, and miR-141, respectively.
To determine the predictive relationships that each biomarker has with one
another, Pearson correlation coefficients were determined and summarized in
tables 7 and 8 for cohort 1 and 2, respectively. As correlation coefficients gets
closer to 1.00, the tighter the relationships two biomarkers have with one another
and can, in theory, predict the same degree of change. Correlation coefficients
for cohort 1 for miR-141 versus PSA was R=0.94 (p<0.001), miR-141 versus
CTC was R=0.65 (p=0.082), and miR-141 versus LDH was R=0.85 (p=0.008).
For cohort 2, miR-141 versus PSA was R=0.63 (p=0.021), miR-141 versus CTC
was R=0.79 (p=0.001), and miR-141 versus LDH was R=0.67 (p=0.013).
A binary classification analysis, although similar to a correlation analysis, was
performed to indicate the sensitivity and specificity of a marker in relation to a
standard. For a correlation analysis, the outcome variables (slope) was plotted
to determine the correlation, a binary classification study differs in that each
slope was assigned binary values based on its regression: either positive or
negative. A positive slope was assigned a value of “1” whereas a negative slope
was assigned a value of “0.” LDH, CTC and miR-141 were subjected as test
outcomes for the classification analysis comparing it individually against PSA,
LDH and CTC values as gold standards. Classification of biomarkers against
miR-141 as a standard was not performed as it is not a conventional marker.
Tables 9 and 10 summarize the classification analysis for cohort 1 and cohort 2,
respectively.
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Since a positive slope is a true indicator of a disease that is progressing (a
marker values that has increased during time point), the percentage of people
who have a positive slope for a tested marker correctly identified as having a
positive slope of the standard is an indicator of a marker’s sensitivity.

The

specificity of a marker is a measure of the proportion of the patients that tested
with a decline of a test marker (negative slope) with a decline of the standard
marker. An overall correct classification was determined by samples that
correctly identified sensitivity and specificity against the whole cohort.
Testing miR-141 against PSA as the standard yielded a sensitivity of 75%,
specificity of 100% and a correct classification of 87.5% in cohort 1. For cohort
2, the same analysis yielded a value of 75%, 80% and 76.9% for sensitivity,
specificity and correct classification, respectively. Performing the same analysis
on CTC with PSA as the standard measured a 75% of all classifications in cohort
1 and a 87.5% sensitivity, 100% specificity and 92.3% overall performance in
cohort 2. In this classification analysis, miR-141 values outperformed the CTC
test in its capability to predict a PSA classification for patients with 1 interval,
whereas with multiple intervals, CTC performed better. Interestingly, LDH did not
perform any better than other two markers in predicting a PSA response. Testing
miR-141 to predict CTC had a sensitivity, specificity and total classification
percentages of 75.0%, 100% and 87.5%, respectively for cohort 1 and 85.7%,
83.3% and 84.6%, respectively for cohort 2.
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Table 1: miR-141 values of control samples
Control
miR-141 Value*
Sample
1
1997
2
1514
3
263
4
159
5
54.0
6
67.6
7
115
8
82.9
9
3.63
10
1.63
* = Copy number/8.35µL

Table 2: Ranges of miR-141 values observed with controls
miR-141 Value
# Samples in
Range*
Range
1-10
2
11-100
3
101-300
3
301-1000
0
1001-3000
2
* = Copy number/8.35µL
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Table 3: Patient biomarker values and clinical assessment
Patient

Draw #

CTC
Value*

PSA
Value†

LDH
Value ‡

miR-141
Value§

Clinical Assessment

1
2
90.4
134
29.8
Interval 1: Progressing rapidly (t = 2 months)
2
40
314.1
1246
135.6
Interval 2: Regressing slowly (t= 2 months)
3
56
238.2
159
760
1
3
4.5
194
595
2
Interval 1: Progressing slowly (t = 13 months)
2
401
9.6
282
5165
1
201
71.8
328
1679
Interval 1: Progressing rapidly during interval. Patient died
3
4 days after draw 2 with liver metastases (t = 3 months)
2
356
173.5
2729
18851
1
0
0.2
311
338
4
Interval 1: Progressing slowly (t = 11 months)
2
9
2.6
219
1479
1
0
85.8
143
142
Interval 1: Progressing slowly (t = 4 months)
5
2
4
152.4
157
227
Interval 2: Stable on treatment (t = 21 days)
3
9
173
168
389
1
3
21.5
205
95.9
2
101
93.0
253.0
1025
Interval 1: Progressing rapidly (t = 2.5 months)
6
Interval 2: Progressing slowly (t= 2.5 months)
3
206
143.2
291.0
1370
**4
326
119.0
141.0
4650
1
0
74.3
155
3337
Interval 1: Progressing slowly during interval (t = 4
7
months)
2
7
9.2
121
589
1
65
288.8
229
950
Interval 1: Net slow regrssion (t = 3 months)
8
2
1
168.0
155.0
99.8
Interval 2: Regressing rapidly (t= 20 days)
3
0
69.7
174.0
36.7
1
72
57.5
212
475
Interval 1: Progressing slowly (t = 5 months)
9
2
12
118.0
262.0
697
Interval 2: Regressing slowly (t= 7 months)
3
1
15.6
N/A
182
1
41
14.3
234
295
Interval 1: Regressing slowly during interval (t = 4
10
months)
2
0
<0.1
159
24.3
1
113
259.1
183
9454
Interval 1: Regressing slowly during interval (t = 2
11
months)
2
0
73.1
156
2559
1
145
2.3
161
1067
Interval 1: Progressing slowly (t = 2 months)
12
2
13
1
151
219
Interval 2: Regressing slowly (t= 4 months)
3
0
2.7
132
201
1
1295
71.8
352
856
Interval 1: Regressing rapidly during interval (t = 6
13
months)
2
1
0.2
278
23.4
1
67
138.1
242
790
14
Interval 1: Progressing rapidly (t = 4.5 months)
2
16
172.5
339
622
1
3
6.1
225
256
Interval 1: Regressing slowly (t = 7 days)
15
2
5
4.9
324
258
Interval 2: Net slow progression (t= 2.5 months)
3
26
17.2
294
1615
1
28
247
188
795
Interval 1: Progressing slowly (t = 5.5 months)
16
2
30
1184
168
349
Interval 2: Net slow progression (t= 2.5 months)
3
273
858
N/A
674
1
0
4
194
119
Interval 1: Progressing slowly (t = 3.5 months)
17
2
2
26.3
200
642
Interval 2: Rapid progression (t= 3 months)
3
17
238
219
1737
1
0
4.8
147
138
Interval 1: Progressing slowly (t = 7 months)
18
2
3
2.4
170
123
Interval 2: Slow progression (t= 1 month)
3
29
18.2
120
427
1
95
44.7
95
63.0
Interval 1: Regressing slowly (t = 2 months)
19
2
2
6.1
87
64.1
Interval 2: Slow regression (t= 2 months)
3
0
3.6
74
94.34
1
9
1.6
215
1152
Interval 1: Net slow progression (t = 4.5 months)
20
2
7
6.4
290
1323
Interval 2: Slow regression (t= 3 months)
3
0
0.3
192
310
1
8
593.2
340
2053
Interval 1: Slow regression (t = 2 months)
21
2
2
51.4
265
1923
Interval 2: Net Slow regression (t= 10.5 months)
3
0
0.2
258
271
Interval 1= time period between draw 1 and draw 2, Interval 2 = time period between draw 2 and draw 3
t = time, * = Number of CTC/7.5mL of blood, † = ng/mL, ‡ = IU/L, § = Copy number/8.35µL as measured by qRT-PCR
** = No raw or statistical analyses were performed with data from patient 6, draw 4
1
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Table 4: Biomarker concordance with clinical assessments
Patient
1
2
3
4
5

6
7
8

9
10
11
12
13
14
15

16

17

18

19

20

21

Draw #
1
2
3
1
2
1
2
1
2
1
2
3
1
2
3
1
2
1
2
3
1
2
3
1
2
1
2
1
2
3
1
2
1
2
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

Clinical Assessment

CTC

Interval 1: Progressing rapidly (t = 2 months)
Interval 2: Regressing slowly (t= 2 months)
Interval 1: Progressing slowly (t = 13 months)
Interval 1: Progressing rapidly during interval. Patient died 4
days after draw 2 with liver metastases (t = 3 months)
Interval 1: Progressing slowly (t = 11 months)
Interval 1: Progressing slowly (t = 4 months)
Interval 2: Stable on treatment (t = 21 days)
Interval 1: Progressing rapidly (t = 2.5 months)
Interval 2: Progressing slowly (t= 2.5 months)
Interval 1: Regressing slowly during interval (t = 4 months)
Interval 1: Net slow regression (t = 3 months)
Interval 2: Regressing rapidly (t= 20 days)
Interval 1: Progressing slowly (t = 5 months)
Interval 2: Regressing slowly (t= 7 months)
Interval 1: Regressing slowly during interval (t = 4 months)
Interval 1: Regressing slowly during interval (t = 2 months)
Interval 1: Progressing slowly (t = 2 months)
Interval 2: Regressing slowly (t= 4 months)
Interval 1: Regressing rapidly during interval (t = 6 months)
Interval 1: Progressing rapidly (t = 4.5 months)**
Interval 1: Regressing slowly (t = 7 days)
Interval 2: Net slow progression (t= 2.5 months)
Interval 1: Progressing slowly (t = 5.5 months)
Interval 2: Net slow progression (t= 2.5 months)
Interval 1: Progressing slowly (t = 3.5 months)
Interval 2: Rapid progression (t= 3 months)
Interval 1: Progressing slowly (t = 7 months)
Interval 2: Slow progression (t= 1 month)
Interval 1: Regressing slowly (t = 2 months)
Interval 2: Slow regression (t= 2 months)
Interval 1: Net slow progression (t = 4.5 months)
Interval 2: Slow regression (t= 3 months)
Interval 1: Slow regression (t = 2 months)
Interval 2: Net Slow regression (t= 10.5 months)
# of intervals
number concordant
% Correct

b
+
b
+
b
+
b
+
b
+
b
+
+
b
b
+
+
b
+
b
+
b
+
b
+
+
b
+
b
b
+
b
+
+
b
+
+
b
+
+
b
+
+
b
+
b
+
+
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Concordance
PSA
LDH
b
+
+
b
+
b
+
b
+
b
+
b
+
+
b
+
b
+
+
b
+
+
b
+
b
+
b
b
+
b
+
b
+
+
b
+
b
+
+
b
+
b
+
+
b
+
+
b
+
+
34

b
+
+
b
+
b
+
b
b
+
b
+
+
b
+
b
+
b
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Figure 5: Fold changes in biomarker values for patients with 2 time points
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Figure 6: Fold changes in biomarker values for patients with 3 time points
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Table 5: Analysis of variance for cohort 1 (patients with 1 interval)

Group 1
Mean
Std
N
Group 2
Mean
Std
N
p-value

PSA

Marker
LDH
CTC

0.189
0.178
4

0.308
0.531
4

0.13
0.479
4

0.394
0.59
4

-0.924
0.135
4

-0.105
0.04
4

-1.521
1.967
4

-0.869
0.194
4

<0.001

0.172

0.154

0.007

miR-141

Table 6: Analysis of variance analysis for cohort 2 (patients with 2 intervals)

Group 1
Mean
Std
N
Group 2
Mean
Std
N
p-value

PSA

Marker
LDH
CTC

0.322
0.262
8

0.006
0.042
8

0.462
0.702
8

0.411
0.493
8

-0.436
0.314
8

-0.028
0.066
8

-0.853
0.687
8

-0.313
0.47
8

<0.001

0.277

0.007

0.024

miR-141

Table 7: Correlation analysis for cohort 1 (patients with 1 interval)

PSA
LDH

vs. LDH
0.68
p=0.065

Marker
vs. CTC
0.66
p=0.074
0.34
p=0.412

CTC
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vs. miR-141
0.94
p<0.001
0.85
p=0.008
0.65
p=0.082

Table 8: Correlation analysis for cohort 2 (patients with 2 intervals)

PSA
LDH

vs. LDH
0.48
p=0.097

Marker
vs. CTC
0.78
p=0.002
0.63
p=0.020

CTC
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vs. miR-141
0.63
P=0.021
0.67
p=0.013
0.79
p=0.001

Table 9: Classification analysis for cohort 1 (patients with 1 interval)

PSA (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification
LDH (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification
CTC (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification

LDH
Decrease Increase
4
0
1
3
75.00%
100.00%

Test Parameter
CTC
Decrease Increase
3
1
1
3
75.00%
75.00%

miR-141
Decrease Increase
4
0
1
3
75.00%
100.00%

87.50%

75.00%

87.50%

Decrease Increase
3
2
1
2
66.70%
60.00%

Decrease Increase
4
1
1
2
66.70%
80.00%

62.50%

75.00%
Decrease Increase
4
0
1
3
75.00%
100.00%
87.50%
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Table 10: Classification analysis for cohort 2 (patients with 2 intervals)

PSA (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification
LDH (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification
CTC (standard)
Decrease
Increase
Sensitivity
Specificity
Correct
classification

LDH
Decrease Increase
4
1
4
4
50.00%
80.00%

Test Parameter
CTC
Decrease Increase
5
0
1
7
87.50%
100.00%

miR-141
Decrease Increase
4
1
2
6
75.00%
80.00%

61.50%

92.30%

76.90%

Decrease Increase
5
3
1
4
80.00%
62.50%

Decrease Increase
5
3
1
4
80.00%
62.50%

69.20%

69.20%
Decrease Increase
5
1
1
6
85.70%
83.30%
84.60%
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CHAPTER 4
DISCUSSION AND CONCLUSION
There is great demand for more specific and sensitive biomarkers for
prognosticating disease progression and determining treatment efficacy in CAP
patients.

It is well known that PSA values can be affected by tumor

differentiation state; where poorly differentiated tumors produce significantly less
PSA compared to tumors with well differentiated cells. Significant differences in
PSA production can lead to false-negatives leading a patient to believe that he is
cancer-free. Despite its inherent shortfalls, the use of PSA levels as a diagnostic
and prognostic marker has been the most commonly used test and seen as the
gold standard in the detection and care of CAP.
There has been major focus in discovering new biomarkers that will facilitate
in the monitoring of disease progression.

Proper monitoring of disease

progression throughout a treatment regimen is vital for increasing a patient’s
chance of survival. The monitoring of disease progression or treatment efficacy
through the detection of biomarkers is ideal in that it requires a less invasive
approach and limits potential harm and discomfort to the patient. As mentioned,
PSA is the gold standard in monitoring CAP; however new approaches such as
detecting circulating tumor cells have been developed and is currently being
used in conjunction with PSA tests.
Discovering new biomarkers associated with disease states can be a
daunting task. Initial efforts in discovering new markers require “fishing” for any
changes or expression levels compared to normal or non-disease cohorts.
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Determining these changes requires numerous gene expression, microarray
analyses or other experimental procedures that detect unique diseaseassociated genetic signatures. These experiments can even be complicated in
the potential lack of samples or a model system.

Once a potential marker

becomes identified, these candidate markers must prove to be sensitive and
specific enough to be given approval for use in clinical testing.
Markers currently approved for clinical use can help in validating a potential
marker’s potential to indicate a possible disease state. Candidate markers can
use approved biomarkers as standards with which to compare its potential
predictive characteristics.

More often, comparative studies would ideally be

performed under a prospective study. For this type of study, the expression of a
putative marker should be determined or tested concomitantly with the standard
marker.

Furthermore, marker values should be compared over time and

determine if there is any correlation or concordance of changes comparable to
the standard. Prospective studies can prove to be difficult to establish due to
potential lack in patients exhibiting the specific disease or the lack of tests being
offered by certain facilities.
In lieu of prospective studies, a retrospective study can be performed on
samples collected and stored in biorepositories.

Many facilities proactively

collect extra biological samples from patients in the anticipation of certain
studies. Unfortunately, retrospective studies can introduce bias in the sample
selection or can risk the degradation of an analyte if the sample is not prepared
or stored properly. Nevertheless, a positive retrospective study can lead to a
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prospective study if evidence suggests a strong correlation between the putative
and standard marker.
In this study, we took a retrospective approach to determine if detectable
miRNA in CAP samples can accurately predict a patient’s prognosis. An initial
study (Mitchell et al., 2008) determined that miR-141 was stable and detectable
in CAP in the plasma of patients. We expanded on their study to compare miR141 with other conventional markers clinically approved for monitoring CAP
prognosis. Furthermore, these studies were performed temporally over either
two or three draw points and determined if these changes over time correlated
with the changes of the other conventional markers, and most importantly, if they
there was concordance with the patient’s clinical outcome.
Although we detected miR-141 in our control population, the control data
proved to be inconclusive. Since control samples are healthy individuals, no
follow-up samples were collected leaving us with only one data point per control;
therefore we cannot determine any temporal changes. Furthermore, no other
clinical values were ascertained limiting our ability to compare the miR-141
values against other markers. The individual data points also demonstrate an
inability to establish any baseline values that can distinguish a healthy individual
from a diseased individual.
We observed a range of miR-141 values from our control samples of1.6
(control sample 10) to 1997 (control sample 1) copy numbers – a difference of
over 1000 fold. However, analyzing the control miR-141 values broken down into
ranges illustrate that 80% of the samples fell between ranges of 1- 300 copy
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numbers, whereas the remaining fell in the range of 1000 or more.

It would be

easy for us to classify the spike in these two samples as outliers from the
remainder of the group, but unfortunately, the control patients were kept
anonymous and their health status was not clinically validated. Perhaps this
illustrates miR-141’s involvement in processes we are not quite aware of at the
moment.

An improvement for a study like this would be the ability to include

validated health statues on control samples. Nonetheless, we found significant
findings in the changes of miR-141 for patients who have progressing or
regressing CAP.
We first sought to determine if raw values of miR-141 could accurately predict
a clinical response by determining any degree of concordance that miR-141
values had with the true clinical assessments. For all of our comparison studies,
PSA was used as the standard. PSA had an 85% concordance with the clinical
assessments whereas CTC and miR-141 had a 79% and 74% concordance,
respectively. This analysis clearly illustrates that, although PSA is considered
the benchmark marker, there is no test that can predict a clinical response with
100% accuracy for CAP. Furthermore, it illustrates that miR-141 has predictive
qualities that can potentially discern a clinical assessment.
Our initial ANOVA study clearly indicates (as expected) that PSA is capable
of differentiating the difference of a progressing or regressing CAP patient. For
both cohorts, p-value for PSA of p<0.001 is a strong indicator that the differences
between the two groups were not by random chance alone. As we compared the
miR-141 p-values, we observed fairly significant values (p=0.007 and p=0.024 for
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cohort 1 and 2, respectively). Meaning, to some degree of confidence, we can
differentiate groups of patients based on miR-141 values. Comparing these pvalues to LDH and CTC for those in cohort 1, we confidently say that miR-141
outperforms LDH and CTC in its ability to properly classify CAP prognosis in
patients with one interval. However, in patients with two interval (cohort 2), the
performance of miR-141 was not as impressive and was outperformed by CTC
(p=0.007CTC vs. p=0.024miR-141). An important observation was made in that LDH
did not outperform any markers in any of the two cohorts for this particular study
Our study of variance also illustrated a high coefficient of variation (CV)
observed for each group and in each cohort with CVs ranging from 30% or
greater. For a translational study such as this, it would be important to limit this
CV to 10% or less. To achieve this, we would need to determine what would be
the sufficient sample size for ensuring a CV of our ideal percentage. Using our
observed means for each marker studied, a confidence interval of 99% and
limiting the margin of error to 1%, it is estimated that we would have needed to
study 663 patients achieve a CV of 10% or less.
We conducted a correlation study to compare the predictive relationship of
each marker versus the standard (PSA).

We observed a high correlation

(R=0.94, p<0.001) of miR-141 for cohort 1; however, these values decreased in
cohort 2 (R=0.63, p=0.021).

Again, the performance of miR-141 in the

correlation study for cohort 1 was significantly better than both CTC and LDH, but
this cannot be said in cohort 2. In cohort 2, CTC (R=0.78, p=0.002) clearly
outperformed the other two analytes.
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Also for cohort 2, we observed a

signification correlation between CTC and miR-141 values (R=0.79, p=0.001),
thus allowing us to conclude that there could potentially be a synergistic quality
between these two analytes in prognosticating CAP.
As for any medical test, it is necessary to determine the predictive value and
accuracy of test in order to be used for clinical settings. To conclude our
statistical analysis of

biomarker comparisons, we performed a binary

classification analysis to determine the sensitivity (true positives) and specificity
(true negatives) of a marker in relation to a gold standard. Performing this type
of comparison would allow us to further conclude the capability that miR-141 can
screen and confirm a CAP prognosis.

This test indicated that miR-141 had

strong classification characteristics compared to CTC and LDH. Although we
only observed an 80% specificity (compared to PSA as gold standard) for cohort
2, we were able to observe 100% specificity for cohort 1.

Furthermore,

comparing the sensitivity and specificity of LDH and CTC against PSA, miR-141
performed better than LDH and comparable to CTC in this classification analysis.
Ideally, any test should have sensitivity and specificity close to 100%, but no
such perfect test exists for CAP.
Our study was designed to evaluate the performance of miR-141 in predicting
clinical outcomes in CAP patients.

Our goal was to determine if temporal

changes of miR-141 correlated with the clinical outcomes of patients and if these
changes concomitantly changed with other conventional biomarkers used in
monitoring and prognosticating CAP.

The study of raw temporal changes,

however, did not allow us to determine a baseline miR-141 copy number value
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that can accurately predict a clinical outcome (meaning we cannot determine an
upper limit of normal). Determining a threshold or baseline miR-141 value would
require a more extensive study involving more patients.
Our statistical analyses were performed on the slopes determined from
plotting two interval points; these slopes are interpreted as the rate of biomarker
change over time. The analysis compared miR-141 changes to the rates of
change observed in the other clinical markers. The correlation and classification
analyses indicate that miR-141 has the potential to be a new biomarker for the
progression of CAP. In some instances, miR-141 outperformed CTCs but in all
cases it performed better than LDH.
For this study, no inference can be made on the mechanisms for miR-141
detection in the bloodstream. However, our ANOVA analysis may point to a link
with PSA and miR-141 secretion into the bloodstream. Perhaps there can also
be a link with miR-141 values and CTCs detected wherein a CTC could possibly
undergo apoptosis or lyse releasing miR-141; however, further characterization
and mechanism of CTC release is needed to characterize any potential links.
Nonetheless, this retrospective study provides evidence that miR-141 has
potential to aid in prognosticating CAP progression or predict response to
treatment; however additional studies need to be performed prospectively with a
much larger sample population to confirm the utility of miR-141.
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APPENDIX
SUPPLEMENTAL DATA
Table A1: Summary of preliminary data obtained our study
Disease

Breast
cancer

Prostate
Cancer

Platform

Analyte
Type

Analyte

Status

Luminex®

Protein

CA-125, IGF-II, Leptin,
MIF, Osteopontin,
Prolactin

Sample procurement
issues hindered further
results

qRT-PCR

Gene
Expression

BMI1 and SALL4

Preliminary results
obtained

Luminex®

Protein

BMI1 and SALL4

Sample procurement
issue hindered
preliminary results

qRT-PCR

Gene
Expression

BMI1 and SALL4

Degradation of analyte
yielded no results

qRT-PCR

microRNA

miR-141

Pilot study completed
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Analyte: Leptin

Analyte: IGF-II

1000

10000

100

1000

Median Neg, 25.52
Median Pos, 17.51

10

Concentration [ng/mL]

Concentration [ng/mL]

Median Neg, 1496.35

1

0.1

Median Pos, 1066.93

100

10

Breast Positive

1

Breast Negative

Analyte: CA-125

Breast Positive

Breast Negative

Analyte: Osteopontin

10000

100

1000

Median Pos, 33.50

10
Median Neg, 3.32

1

Concentration [ng/mL]

Concentration [IU/mL]

10
100

1

Median Pos, 1.22

0.1
Median Neg, 0.07

0.1

0.01

Breast Positive

0.01

Breast Negative

Analyte: MIF
100

10
Median Pos, 31.5
Median Neg, 15.15

10

Concentration [ng/mL]

100
Concentration [pg/mL]

Breast Negative

Analyte: Prolactin

1000

1

0.1

Breast Positive

Median Pos, 2.46

Median Neg, 2.35

1

0.1

Breast Positive

0.01

Breast Negative

Breast Positive

Breast Negative

Figure A1: 6-analyte assay of breast cancer patients. Samples of serum normal
women and breast cancer patients were subjected to a 6-analyte, Luminex®based biomarker panel obtained from Millipore. Our objective was to determine
the utility of this marketed biomarker panel in detecting and differentiating breast
cancer patients from normal samples. Policies in samples procurement hindered
attempts to follow-up with results and perform more studies.
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Gene Expression of Bmi1
10000

Relative Quantification (Log)

1000

100
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1

0.1

0.01
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Stage III/IV

Gene Expression of SALL4
100000

Relative Quatification (Log)

10000

1000

100

10

1

0.1

Controls

Stage I/II

Stage III/IV

Figure A2: SALL4 and BMI1 gene expression assay on breast cancer patient
serum. In-house developed multiplex TaqMan gene expression assay was
performed to determine relative quantification of SALL4 and BMI1 in breast
cancer patients with varying stages of disease progression. Policies in samples
procurement hindered attempts to follow-up with results and perform more
studies.
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